PBLS Parabilis Medicines
Parabilis Medicines earnings company data as of 4:48 AM ET 10/23
History
2 periods, newest first. Each row shows EPS above revenue.
| Period | Date | Metric | Estimate | Actual | Result |
|---|---|---|---|---|---|
| FY2026 Q3 | 12 Nov | EPS | — | — | — |
| Rev | — | — | — | ||
| FY2026 Q2 | 13 Aug | EPS | — | -2.32 | — |
| Rev | — | $100.0K | — |
Insider trades
Open-market buys and sales by PBLS's executives, directors and 10% owners in the last 12 months, from their Form 4s
- $441M bought by 3 insiders
- None no sales outside a trading plan
- None no planned (10b5-1) sales
-
Ra Capital Management, L.P. Director, +4 joint filersBuy$6.9M 244,593 shares at $28.29 +0.9% to stakeTraded Jul 20–22 Filed Jul 22
-
Guy Levy 10% owner, +8 joint filersBuy$10M 500,000 shares at $20.00 +329% to stakeTraded Jun 11 Filed Jun 29
-
Alan Sebulsky DirectorBuy$474K 17,500 shares at $27.06 +140% to stakeTraded Jun 12–15 Filed Jun 16
-
Ra Capital Management, L.P. Director, +4 joint filersBuy$424M 21.2M shares at $20.00 New stakeTraded Jun 11 Filed Jun 15
-
Alan Sebulsky DirectorBuy$250K 12,500 shares at $20.00 New stakeTraded Jun 11 Filed Jun 15
Also filed in the last 12 months, not counted as buying or selling: 15 conversions.
SEC filings
Recent issuer filings from EDGAR, 14 shown.
| Filed | Form | Detail | Links |
|---|---|---|---|
| 8-K | 7.01 | Filing Doc | |
| 8-K | 5.02 | Filing Doc | |
| 8-K | 5.02,7.01,9.01 | Filing Doc | |
| SCHEDULE 13G | — | Filing Doc | |
| 8-K | 2.02,7.01,9.01 | Filing Doc | |
| 10-Q | Filing Doc | ||
| SCHEDULE 13G | — | Filing Doc | |
| SCHEDULE 13D | — | Filing Doc | |
| 8-K | 1.01,3.02,5.03,9.01 | Filing Doc | |
| 424B4 | Filing Doc | ||
| S-1/A | Filing Doc | ||
| S-1/A | Filing Doc | ||
| S-1/A | Filing Doc | ||
| S-1 | Filing Doc |
No filings match this filter.
Estimates are consensus figures; SEC filings remain the official record. Not investment advice.